Stock Events

Stock Events

Valbiotis SA 

€1.02
37
+€0.08+8.05% Wednesday 07:11

Statistics

Day High
1.02
Day Low
1.02
52W High
1.29
52W Low
0.53
Volume
-
Avg. Volume
-
Mkt Cap
24.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

2MarExpected
Q2 2023
Q1 2024
Q1 2024
Q3 2024
Q4 2024
Q3 2025
Q4 2025
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,040.55%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.81MRevenue
-18.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 8JD.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Valbiotis' focus on metabolic diseases.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a multinational pharmaceutical company that has a strong portfolio in diabetes and cardiovascular diseases, making it a direct competitor to Valbiotis.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly is a global pharmaceutical company with significant investments in diabetes and metabolic disorders, competing in the same space as Valbiotis.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, directly competing with Valbiotis' product offerings.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company with a focus on chronic diseases such as diabetes, directly competing with Valbiotis' research and development in metabolic disorders.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical corporation with a broad product portfolio that includes treatments for metabolic disorders, competing with Valbiotis.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on cardiovascular disease and has been expanding its portfolio in metabolic disorders, making it a competitor to Valbiotis.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company with a strong emphasis on chronic diseases, including metabolic disorders, competing with Valbiotis.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb has a diverse portfolio in cardiovascular and metabolic diseases, positioning it as a competitor to Valbiotis.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline has a focus on developing new treatments for diabetes and obesity, areas that Valbiotis is also targeting.

About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Show more...
CEO
Mr. Sebastien Peltier HDR, Ph.D.
Employees
44
Country
FR
ISIN
FR0013254851
WKN
000A2DS5F

Listings

F
DE
8JD.F
PA
FR
ALVAL.PA

0 Comments

Share your thoughts

FAQ

What is Valbiotis SA stock price today?▼
The current price of 8JD.F is €1.02 EUR — it has increased by +8.05% in the past 24 hours. Watch Valbiotis SA stock price performance more closely on the chart.
What is Valbiotis SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Valbiotis SA stocks are traded under the ticker 8JD.F.
Is Valbiotis SA stock price growing?▼
8JD.F stock has risen by +3.55% compared to the previous week, the month change is a +5.37% rise, over the last year Valbiotis SA has showed a -0.78% decrease.
What is Valbiotis SA market cap?▼
Today Valbiotis SA has the market capitalization of 24.17M
What is Valbiotis SA revenue for the last year?▼
Valbiotis SA revenue for the last year amounts to 1.81M EUR.
What is Valbiotis SA net income for the last year?▼
8JD.F net income for the last year is -18.83M EUR.
How many employees does Valbiotis SA have?▼
As of April 02, 2026, the company has 44 employees.
In which sector is Valbiotis SA located?▼
Valbiotis SA operates in the Health Care sector.
When did Valbiotis SA complete a stock split?▼
Valbiotis SA has not had any recent stock splits.
Where is Valbiotis SA headquartered?▼
Valbiotis SA is headquartered in Périgny, FR.